• Filament Health, a wholly owned unit of Rhelion Life Sciences, signed a licence and supply deal with UCSF for its psilocybin candidate PEX010.
• PEX010 will be used in UCSF’s Phase 2 PRISM trial in people with HIV who have moderate to severe methamphetamine use disorder.
• Study plans to enroll 30 participants, testing a single monitored dose of 25 mg versus 5 mg as an active comparator.
• Trial is expected to start in November 2026 at Zuckerberg San Francisco General Hospital; primary endpoints include feasibility and safety.
• Filament will supply 25 mg and 5 mg capsules for U.S. use, supported by manufacturing and regulatory documentation for the IND.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhelion Life Sciences Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610080819NEWSFILECNPR____20261008_318082_1) on October 08, 2026, and is solely responsible for the information contained therein.